Cigarette smoking, appendectomy and tonsillectomy as risk factors for the development of primary sclerosing cholangitis (PSC): A case control study.

Cigarette smoking, appendectomy and tonsillectomy as risk factors for the development of primary sclerosing cholangitis (PSC): A case control study.

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς:	Mitchell, SA, Thyssen, M, Mitchell, M, Orchard, T, Jewell, D, Fleming, K, Chapman, R
Μορφή:	Journal article
Έκδοση:	1998

Παρόμοια τεκμήρια

Cigarette smoking, appendectomy, and tonsillectomy as risk factors for the development of primary sclerosing cholangitis: a case control study.
ανά: Mitchell, SA, κ.ά.
Έκδοση: (2002)

Cytokine profiles in primary sclerosing cholangitis (PSC) and autoimmune liver diseases: Comparing expression in the periphery and the liver.
ανά: Mitchell, SA, κ.ά.
Έκδοση: (1997)

Primary sclerosing cholangitis.
ανά: Mitchell, SA, κ.ά.
Έκδοση: (2000)

Enhanced cytokine mRNA expression in Primary Sclerosing Cholangitis (PSC) and autoimmune liver diseases.
ανά: Mitchell, S, κ.ά.
Έκδοση: (1997)

ADHESION MOLECULE EXPRESSION IN PRIMARY SCLEROSING CHOLANGITIS (PSC)
ανά: Bloom, S, κ.ά.
Έκδοση: (1992)

The management of primary sclerosing cholangitis.
ανά: Mitchell, SA, κ.ά.
Έκδοση: (1998)

TISSUE DISTRIBUTION OF AN AUTOANTIGEN SPECIFIC FOR PRIMARY SCLEROSING CHOLANGITIS (PSC)
ανά: Lo, S, κ.ά.
Έκδοση: (1992)

Deposition of complement C9 in primary sclerosing cholangitis (PSC).
ανά: Shanahan, J, κ.ά.
Έκδοση: (1998)

IMMUNOGENETIC FACTORS IN THE CLINICAL COURSE OF PRIMARY SCLEROSING CHOLANGITIS (PSC)
ανά: Mehal, W, κ.ά.
Έκδοση: (1993)

Down regulation of interferon gamma and up regulation of interleukin-10 by ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC).
ανά: Mitchell, SA, κ.ά.
Έκδοση: (1997)

Role of interleukin-10 in the pathogenesis of primary sclerosing cholangitis and primary biliary cirrhosis?
ανά: Mitchell, SA, κ.ά.
Έκδοση: (1998)

Review article: the management of primary sclerosing cholangitis.
ανά: Mitchell, SA, κ.ά.
Έκδοση: (1997)

New time dependent prognostic models for primary sclerosing cholangitis (PSC)
ανά: Rocca, G, κ.ά.
Έκδοση: (2000)

INAPPROPRIATE EXPRESSION OF BLOOD-GROUP ANTIGENS ON THE BILIARY EPITHELIUM IN PRIMARY SCLEROSING CHOLANGITIS (PSC)
ανά: Bloom, S, κ.ά.
Έκδοση: (1990)

Primary sclerosing cholangitis: what is the role of ursodeoxycholic acid in therapy for PSC?
ανά: Chapman, R
Έκδοση: (2010)

Primary sclerosing cholangitis--an immunologically mediated disease?
ανά: Chapman, R, κ.ά.
Έκδοση: (1985)

Liver cell proliferation in primary sclerosing cholangitis (PSC), as assessed by anti-KI-67 labelling.
ανά: Shanahan, J, κ.ά.
Έκδοση: (1998)

PORTAL TRACT LYMPHOCYTE POPULATIONS IN PRIMARY SCLEROSING CHOLANGITIS
ανά: Snook, J, κ.ά.
Έκδοση: (1987)

ANTINEUTROPHIL ANTIBODY AND PRIMARY SCLEROSING CHOLANGITIS
ανά: Lo, S, κ.ά.
Έκδοση: (1991)

Primary sclerosing cholangitis
ανά: Chapman, R
Έκδοση: (2007)

Primary sclerosing cholangitis.
ανά: Chapman, R
Έκδοση: (1985)

High dose ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): Results after two years of a randomised double-blind, placebo-controlled trial.
ανά: Mitchell, SA, κ.ά.
Έκδοση: (1997)

Primary sclerosing cholangitis.
ανά: Cullen, S, κ.ά.
Έκδοση: (2003)

A regulatory polymorphism of the stromelysin gene (MMP-3) strongly influences susceptibility to primary sclerosing cholangitis (PSC) and progression to portal hypertension.
ανά: Satsangi, J, κ.ά.
Έκδοση: (2000)

Primary sclerosing cholangitis.
ανά: Williamson, K, κ.ά.
Έκδοση: (2014)

Primary sclerosing cholangitis.
ανά: Worthington, J, κ.ά.
Έκδοση: (2006)

Primary sclerosing cholangitis
ανά: Chapman Roger, κ.ά.
Έκδοση: (2006-10-01)

Decreased interleukin-10 mRNA expression in primary sclerosing cholangitis and primary biliary cirrhosis: A role for IL10 in the pathogenesis?
ανά: Mitchell, SA, κ.ά.
Έκδοση: (1997)

A preliminary trial of high-dose ursodeoxycholic acid in primary sclerosing cholangitis.
ανά: Mitchell, SA, κ.ά.
Έκδοση: (2001)

Characterization of the antigen for the antineutrophil cytoplasmic antibody specific for primary sclerosing cholangitis (PSC) ulcerative colitis (UC).
ανά: Cameron, B, κ.ά.
Έκδοση: (1998)

OLIGONUCLEOTIDE DNA TYPING ANALYSIS OF THE HLA DRB3 LOCUS IN PATIENTS WITH PRIMARY SCLEROSING CHOLANGITIS (PSC)
ανά: Mehal, W, κ.ά.
Έκδοση: (1991)

INTERFERON-GAMMA PRODUCTION IN PRIMARY SCLEROSING CHOLANGITIS
ανά: Martins, E, κ.ά.
Έκδοση: (1995)

ANTI-NEUTROPHIL NUCLEAR ANTIBODY IN INFLAMMATORY BOWEL-DISEASE AND PRIMARY SCLEROSING CHOLANGITIS
ανά: Snook, J, κ.ά.
Έκδοση: (1988)

Is the 308 polymorphism in the tumor necrosis factor (alpha) (TNF alpha) promoter region a marker of disease susceptibility in European patients with primary sclerosing cholangitis (PSC)?
ανά: Mitchell, SA, κ.ά.
Έκδοση: (1998)

The management of primary sclerosing cholangitis.
ανά: Chapman, R
Έκδοση: (2003)

The immunology of primary sclerosing cholangitis.
ανά: Chapman, R
Έκδοση: (1990)

Primary sclerosing cholangitis - Foreword
ανά: Chapman, R
Έκδοση: (2006)

THE IMMUNOGENETICS OF PRIMARY SCLEROSING CHOLANGITIS
ανά: Chapman, R
Έκδοση: (1993)

High dose ursodeoxycholic acid (UDCA) in primary sclerosing cholangitis (PSC): Results after two years of a randomised double-blind, placebo-controlled trial.
ανά: Mitchell, S, κ.ά.
Έκδοση: (1997)

Tissue distribution of autoantigen specific for primary sclerosing cholangitis.
ανά: Lo, S, κ.ά.
Έκδοση: (1993)